checked

things people say about psychiatric medication, diagnosis and the health system, on podcasts and on youtube, taken to the primary record. not a gotcha. the people repeating these claims are mostly right to distrust the standard story, and the only honest way to join that conversation is to go and look, and to say so just as loudly when the claim holds up.

how it works: we quote one sentence, with the show, the date and the timestamp, and link the original. we pull the claim apart into assertions and check each one against the record itself (pubmed abstracts, fda labels, cms and medicaid files, samhsa, nimh, gao, court dockets), never from memory and never from advocacy sites. each assertion gets one of six verdicts, and the page says what the data cannot answer, our own method included. speakers are described by their role on the show, not named.

the six verdicts

• confirmedthe primary source says it, at that magnitude
• undersoldthe real number is bigger, or worse, than claimed
• overstateddirectionally right; magnitude or certainty inflated
• misattributeda real number attached to the wrong thing
• unverifiableno method, no file, or the data cannot answer it
• falsethe primary source contradicts it

the ratio, so far: 36 of 56 assertions came back confirmed or undersold. if that number stays low for long, the pipeline is selecting for outrage and gets re-pointed.

every check

1. confirmedHuberman Lab·2026-10-01·5 primary sources

   do adhd stimulants and modafinil all increase dopamine in the brain

   “there is of course aderall, rolin, vivance, modafanyl, arm modafanyl, a number of different compounds, all of which generally increase dopamine transmission in the brain.” — a host, a neuroscientist, at 33:05

   The core of the statement holds up. FDA labels say amphetamines (including the dextroamphetamine that lisdexamfetamine turns into) and methylphenidate block dopamine reuptake and increase dopamine release. The modafinil and armodafinil labels say both drugs bind the dopamine transporter and block dopamine reuptake, and a human PET study measured higher extracellular dopamine after therapeutic doses of modafinil.

2. confirmedPsychopharmacology and Psychiatry Updates·2026-09-23·4 primary sources

   does adding aripiprazole to another antipsychotic reliably lower prolactin?

   “aeripipyzole specifically if you add it to an antipsychotic, it will actually reliably lower prolactin levels.” — a guest, a professor of psychiatry at Harvard Medical School, at 05:45

   the core of the claim holds up. in randomized trials, adding aripiprazole to a prolactin-raising antipsychotic lowers prolactin more than placebo does, and a 2022 network meta-analysis rated the evidence for adjunctive aripiprazole as high certainty.

3. confirmedLex Fridman Podcast·2026-09-21·4 primary sources

   do antidepressants beat placebo by only one or two points on depression scales?

   “if you improve on one of the major scales that's used by one or two points on a 60-point scale, it may be enough to show statistical significance” — a guest, a historian of psychiatry (Andrew Scull), at 09:24

   the speaker has the size right. on the scale most antidepressant trials used, the average gap between drug and placebo is about 1.8 to 2.1 points. that number is statistically solid, and it falls below the clinical-benefit cutoffs those same papers cite.

4. confirmedHuberman Lab·2026-09-28·5 primary sources

   is compass pathways' psilocybin therapy close to fda approval?

   “psilocybin coming from Compass uh a company called Compass Pathways is also close.” — a guest, author and journalist, at 1:48:38

   the speaker is right: compass pathways' psilocybin program for treatment-resistant depression is the closest any classic psychedelic has come to a u.s. approval decision. two phase 3 trials met their primary endpoints, the fda allowed a rolling new drug application and gave the program a national priority voucher, and the company expects to finish its submission in q4 2026.

5. confirmedThe Peter Attia Drive·2026-10-05·4 primary sources

   do guidelines recommend depression screening during pregnancy and after birth?

   “Um we do have standard screening that's recommended during you know both during pregnancy for depression and um postpartum.” — a guest, an obstetrician (maternal-fetal medicine physician-scientist), at 34:23

   the speaker is right. US guidelines recommend screening for depression both during pregnancy and after birth: the US Preventive Services Task Force does, obstetricians' and pediatricians' professional bodies have written guidance on it, and the task force's statement names pregnant and postpartum persons explicitly.

6. confirmedLex Fridman Podcast·2026-09-21·3 primary sources

   do 40% or more of people with depression not respond to antidepressants?

   “We're talking 40 or north of 40% who aren't responding.” — a guest, a historian of psychiatry (Andrew Scull), at 11:48

   the number holds up. in the largest real-world antidepressant study the US government funded, about half of patients did not respond to the first drug they were given, so "40 or north of 40%" is a fair, even conservative, way to put it.

7. confirmedHuberman Lab·2026-09-28·3 primary sources

   does one executive order fast-track both ibogaine and other psychedelics?

   “The same um executive order that um is fasttracking Ibeane is fasttracking other psychedelics.” — a guest, author and journalist, at 1:48:17

   the speaker is right. a single executive order, EO 14401 of april 18, 2026, names ibogaine and also directs federal agencies to speed up psychedelic drugs more broadly, so "the same order" covers both.

8. confirmedPsychopharmacology and Psychiatry Updates·2026-09-29·3 primary sources

   did the fda approve trazodone for depression in 1981?

   “The FDA approved Trasadone for depression back in 1981.” — a host, at 01:19

   the host has this right. FDA's own approval database shows trazodone's original application was approved on december 24, 1981, as a new molecular entity, and the FDA label lists depression as the condition it treats.

9. falseHuberman Lab·2026-09-28·4 primary sources

   is ibogaine on track for fda approval before mdma or psilocybin?

   “Ibagane, the one psychedelic that no one's would even want to use recreationally, is going to get there first.” — a host, at 1:47:42

   ibogaine does have real federal momentum. an april 2026 executive order names "ibogaine compounds" twice, and on october 5, 2026 the fda put out a formal request for input on how ibogaine trials should be run, alongside early-phase trials funded by arpa-h and nida.

10. overstatedHuberman Lab·2026-09-28·3 primary sources

    has ibogaine never been tested in university drug trials?

    “hasn't been, by the way, subjected to university drug trials,” — a guest, author and journalist, at 1:47:50

    the most prominent university work on ibogaine, the stanford veterans study, is not a drug trial: stanford measured veterans before and after treatment, but the ibogaine itself was given at a private clinic near tijuana, and the paper says "stanford played no role in ibogaine administration." no randomized, placebo-controlled trial run by a university has shown that ibogaine itself works, and a 2026 review of thirty years of research says the evidence is not yet enough to support clinical use.

11. confirmedThe Peter Attia Drive·2026-10-05·3 primary sources

    was medicaid postpartum coverage limited to 60 days before states extended it?

    “Um it's been like 60 60 days.” — a guest, an obstetrician (maternal-fetal medicine physician-scientist), at 55:03

    the speaker is right. federal medicaid law has long required pregnancy-related coverage through a 60-day postpartum period, and before 2022 most states stopped coverage at that point.

12. confirmedHuberman Lab·2026-10-01·6 primary sources

    are methylphenidate, modafinil and armodafinil all stimulants used for adhd?

    “rolin, modafanyl, arm modafanyl, all these things are stimulants.” — a host, a neuroscientist, at 34:24

    The speaker is right that all three are treated as stimulants in the federal record. Methylphenidate's label calls it a central nervous system stimulant. The drug enforcement agency's rule scheduling modafinil calls it "a central nervous system (CNS) stimulant", and that rule covers its isomers, which includes armodafinil.

13. overstatedLex Fridman Podcast·2026-09-21·3 primary sources

    does nice tell clinicians in england to use cbt rather than antidepressants first?

    “groups like NICE in England are saying use CBT as the first line, not drugs.” — a guest, a historian of psychiatry (Andrew Scull), at 11:07

    this part is true: england's depression guideline (nice ng222, june 2022) tells clinicians not to routinely offer antidepressants as first-line treatment for less severe depression unless the person makes an informed choice to take them, and cbt is one of the first-line options it recommends. in the evidence review nice commissioned, antidepressants showed no evidence of effect in less severe depression, and group cbt did.

14. confirmedHuberman Lab·2026-10-01·5 primary sources

    is taking someone else's adhd stimulant illegal and risky for addiction and side effects?

    “they can have a number of other side effects outside the context of clinically diagnosed and prescribed ADHD medication.” — a host, a neuroscientist, at 35:17

    The claim holds up. In the u.s., having a prescription stimulant you weren't prescribed is a federal crime, and the fda's own 2023 safety notice says nonmedical use is linked to a higher risk of substance use disorder and can lead to overdose and death.

15. confirmedHuberman Lab·2026-10-01·4 primary sources

    do stimulants calm children with adhd instead of making them more hyperactive?

    “giving that to a kid who has severe ADHD, you would think would make them rem more rambunctious, less able to focus, and more distractable overall.” — a host, a neuroscientist, at 34:12

    the speaker is right on the main point: in randomized trials, stimulants given to children with adhd lower hyperactivity and inattention ratings over the short term. they do not make those symptoms worse.

16. confirmedPsychopharmacology and Psychiatry Updates·2026-09-29·3 primary sources

    did blurred vision have an odds ratio of 18 in the trazodone-for-sleep-in-depression meta-analysis?

    “As per side effects, blurred vision was most common with an odds ratio of 18 compared to placebo.” — a guest, Dr. Paul Sarkowski (clinician presenting the meta-analysis), at 05:02

    The number is real. A 2026 meta-analysis of trazodone for sleep problems in depression reports an odds ratio for blurred vision of 17.50, which rounds to the 18 the speaker gave.

17. misattributeda Substack newsletter·2026-03-10·4 primary sources

    are toddlers on medicaid being put on anti-anxiety drugs in large numbers

    “we call it medicine: the mass psychiatric drugging of poor children” — a author, a clinical psychologist writing on his own newsletter, at 00:00

    The underlying worry is real and the public record backs it: in the 2025 reporting year the median state documented first-line psychosocial care for only 59.2 percent of children aged 1 to 11 starting an antipsychotic, got both required metabolic blood tests for 29.1 percent of young children on two or more antipsychotic prescriptions, and saw 47.6 percent of children newly prescribed an ADHD medicine again within 30 days. Those are the states' own numbers.

what this is not

not medical advice, and not a reason to start, stop or change a medication; those decisions belong with the person taking it and their prescriber. not a takedown of any host or guest: small true errors stay off the public reply and live only here, because including them turns a contribution into a takedown. and not a feed we re-host: every entry links the original at the timestamp and quotes one sentence under fair use.

if you have the file behind a claim we marked unverifiable, we want it. the research board is the place; people can answer there.